Skip to main content

Amgen: It Could Win The Latest Patent Battle; Will It Matter?

The battle between Amgen and Regeneron over the patent for a new cholesterol drug continues. An appeals court hearing yesterday has Regeneron hoping to overturn a lower court ruling that favored its rival. One analyst handicaps an Amgen victory at 55%. But win or lose, there are problems on the horizon.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.